Presentations will be held by CEO Peter Nordkild, founder and Chief Science Officer Professor Torbjörn Bäckström, as well as other leading experts in the field. The aim of the day is to increase understanding of Asarina Pharma’s research into PMDD, menstrual migraine and Tourette syndrome.
The R&D Day will be held at Helio GT30, Grev Turegatan 30 in Stockholm from 14.00-17.00 on Thursday 26th March.
Please register for the R&D Day by following this link: https://financialhearings.com/event/12602/register/live_event
A formal invitation including a full program for the event will be sent out and will also be available at www.asarinapharma.com
We look forward to meeting you!
This information was provided by Asarina Pharma AB (publ) for publishing on February 4, 2020 at 17.00 CET.